Sylvester researchers develop automated system to calculate metabolic tumor volume in DLBCL

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment

Vasan Yegnasubramanian, MD, PhD, is the director of Precision inHealth Medicine at Johns Hopkins. He spoke with Johns Hopkins Kimmel Cancer Center communications staff about how AI is transforming cancer research and treatment. The transcript of the conversation follows.

March 06, 2026

Vol.52 No.09

By John’s Hopkins Kimmel Cancer Center Communications

Clinical Roundup

AI-based liquid biopsy may detect liver fibrosis, cirrhosis, and broader chronic disease signals, Johns Hopkins researchers find

Researchers at the Johns Hopkins Kimmel Cancer Center report that an artificial intelligence-based liquid biopsy test using genome-wide cell-free DNA fragmentation patterns and repeat landscapes can detect early liver fibrosis and cirrhosis, and may also reveal signals of broader chronic disease burden.

March 06, 2026

Vol.52 No.09

Podcast

Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era

Two lawsuits filed within days of each other in the U.S. District Court for the Northern District of Illinois claimed that Tempus AI Inc., an AI-driven precision and genomic testing company, had violated the Illinois Genetic Information Privacy Act when it acquired Ambry Genetics and started to integrate its genetics data into its predictive models.

March 04, 2026

Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable”

Two lawsuits filed within days of each other in the U.S. District Court for the Northern District of Illinois claim that Tempus AI Inc. had violated the Illinois Genetic Information Privacy Act when it acquired Ambry Genetics and started to integrate its genetics data into its predictive models.

“Lock-and-key” chemistry platform may keep therapeutic drugs inactive until they reach a tumor, Syracuse-led study finds

Many therapeutic molecules used in cancer treatments are highly toxic, often harming healthy tissues and causing significant side effects. This creates a critical need for strategies that localize their toxic activity to tumors. What if cancer drugs could stay dormant until they reach cancer cells? A study by Syracuse University researchers demonstrates a promising chemistry-based strategy that could do just that.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Exercise during chemotherapy for breast cancer improves quality of life, Sylvester-led study finds

For many women with breast cancer, the treatment that saves their lives also brings fatigue that clings like a heavy coat, loss of muscle mass that turns everyday tasks into obstacles and emotional strain that lingers long after each infusion ends. It’s a season defined not just by survival, but by how well patients are able to live through it.

February 27, 2026

Vol.52 No.08

Sylvester researchers develop automated system to calculate metabolic tumor volume in DLBCL

YOU MAY BE INTERESTED IN

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment

AI-based liquid biopsy may detect liver fibrosis, cirrhosis, and broader chronic disease signals, Johns Hopkins researchers find

Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era

Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable”

“Lock-and-key” chemistry platform may keep therapeutic drugs inactive until they reach a tumor, Syracuse-led study finds

Exercise during chemotherapy for breast cancer improves quality of life, Sylvester-led study finds

Renew today!

Subscriber content

Never miss an issue!

Login

Sylvester researchers develop automated system to calculate metabolic tumor volume in DLBCL

YOU MAY BE INTERESTED IN

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment

AI-based liquid biopsy may detect liver fibrosis, cirrhosis, and broader chronic disease signals, Johns Hopkins researchers find

Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era

Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE“Deidentified” ≠ “deidentifiable”

“Lock-and-key” chemistry platform may keep therapeutic drugs inactive until they reach a tumor, Syracuse-led study finds

Exercise during chemotherapy for breast cancer improves quality of life, Sylvester-led study finds

Never miss an issue!

Login

Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable”